Pharma feed

Johnson & Johnson
Normanobserver· 23 Nov 2017

Gareth Morgan Investments Limited Partnership Has Cut Johnson & Johnson (JNJ) Position By $356,532; Southern Copper (SCCO) Had 2 Bulls

Gareth Morgan Investments Limited Partnership Has Cut Johnson & Johnson (JNJ) Position By $356,532; Southern Copper (SCCO) Had 2 Bulls November 23, 2017 - By Richard Conner Gareth Morgan Investments Limited Partnership decreased Johnson & Johnson (JNJ) stake by 17.34% reported in 2017Q2 SEC filing.

  • Johnson & Johnson
  • Southern Copper Corp
  • Morgan Group
  • Partnerships & Alliances
  • Company Websites
Boehringer Ingelheim GmbH
Zenopa· 23 Nov 2017

Boehringer Ingelheim partners with ISFM Cat Friendly Clinic programme

Boehringer Ingelheim partners with ISFM Cat Friendly Clinic programme 23 November 2017 Animal Health Supplier News Boehringer Ingelheim has announced a new partnership with the International Society of Feline Medicine's (ISFM's) Cat Friendly Clinic programme. The scheme, which was established by the veterinary division of the UK-based charity International Cat Care, was developed to raise the standards of care and welfare for cats in the veterinary clinic, offering practical solutions to problems vets face when dealing with felines.

  • Boehringer Ingelheim GmbH
  • Friendly
  • Partnerships & Alliances
  • Press Releases
  • Company Websites
Merck & Co., Inc.
Lifesciencesipreview· 23 Nov 2017

EU General Court backs Endoceutics over Merck trademark use

roschetzky / iStockphoto The EU General Court has backed Endoceutics, a pharmaceutical company focused on women’s health, by revoking a finding that Merck KGaA had genuinely used a trademark. In a decision handed down on Friday, November 17, the General Court annulled a decision which had maintained Merck’s trademark for particular uses.

  • Merck & Co., Inc.
  • Regulatory & Legal
  • Press Releases
  • Company Websites
N
Merck & Co., Inc.
EIN News · 23 Nov 2017

Merck Foundation Conducts 3rd UNESCO-Merck Africa Research Summit in partnership with the Office of President, Mauritius

Dignitaries at the UNESCO-MARS 2016 UNESCO MARS brings together researchers from across Africa to discuss the generation, sharing and dissemination of research data. NAIROBI, KENYA, November 23, 2017 /EINPresswire.com/ -- • UNESCO MARS brings together researchers from across Africa to discuss the generation, sharing and dissemination of research data and to prepare for the road ahead in Africa’s development as an international hub for excellence in scientific innovation.

  • Merck & Co., Inc.
  • Partnerships & Alliances
  • Events
  • News Articles
  • News and Other Websites
Johnson & Johnson
Firstwordpharma· 23 Nov 2017

European Commission approves Johnson & Johnson's Tremfya for plaque psoriasis

Johnson & Johnson's Janssen-Cilag unit announced Thursday that the European Commission approved Tremfya (guselkumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The drug, which selectively blocks IL-23, was authorised by the FDA in July for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

  • Johnson & Johnson
  • FirstWord Pharma
  • Regulatory & Legal
  • Company Websites
N
Teva Pharmaceutical Industries Ltd
Reuters· 23 Nov 2017

Teva Pharmaceutical set for major layoffs in Israel, U.S.: report

TEL AVIV (Reuters) - Teva Pharmaceutical Industries is expected to cut 20-25 percent of its 6,860 workers in Israel and a few thousand more in the United States, financial news website Calcalist reported on Thursday. The world’s largest generic drugmaker will send termination letters to “tens of percents” of its 10,000 employees in the United States in upcoming weeks, Calcalist reported, citing people familiar with the matter.

  • Teva Pharmaceutical Industries Ltd
  • Michael Hayden
  • Cost Cutting
  • News Articles
  • News and Other Websites
Johnson & Johnson
Norcalrecord· 23 Nov 2017

Consumer blames Johnson & Johnson for cancer

Sandra Hubler filed a complaint Oct. 30 in Fresno County Superior Court against Johnson & Johnson, Johnson & Johnson Consumer Companies Inc., Imerys Talc America Inc. and Does 1-100, alleging they failed to exercise reasonable care in the distribution of a consumer product.

  • Imerys
  • Johnson & Johnson
  • Johnson & Johnson Consumer Inc.
  • Regulatory & Legal
  • Negative News
  • Company Websites
N
GlaxoSmithKline PLC
Fox Business· 23 Nov 2017

GlaxoSmithKline Files Additional Trelegy Ellipta Application to FDA

GlaxoSmithKline PLC (GSK.LN) said Thursday that it has filed a supplemental new drug application with the U.S. Food and Drug Administration to support an expanded label for its inhaler Trelegy Ellipta. Continue Reading Below The application is to expand the treatment's indication so that physicians can use it to treat chronic obstructive pulmonary disease patients who require triple therapy, the company said.

  • GlaxoSmithKline PLC
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
GlaxoSmithKline PLC
Dispatchtribunal· 23 Nov 2017

Contrasting GlaxoSmithKline PLC (GSK) & Its Rivals

GlaxoSmithKline PLC (NYSE: GSK) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare GlaxoSmithKline PLC to related companies based on the strength of its institutional ownership, valuation, dividends, profitability, risk, earnings and analyst recommendations.

  • GlaxoSmithKline PLC
  • Competitive Landscape
  • Company Websites
GlaxoSmithKline PLC
Utahherald· 23 Nov 2017

Community Financial Services Group Upped Glaxosmithkline Plc (GSK) Holding By $340,947; Crossvault Capital Management Has Raised Its J P Morgan Chase (JPM) Holding

Community Financial Services Group Upped Glaxosmithkline Plc (GSK) Holding By $340,947; Crossvault Capital Management Has Raised Its J P Morgan Chase (JPM) Holding November 22, 2017 - By Linda Rogers Community Financial Services Group Llc increased Glaxosmithkline Plc (GSK) stake by 7.62% reported in 2017Q2 SEC filing.

  • GlaxoSmithKline PLC
  • Morgan Group
  • JPM Group
  • Funding Activity
  • Company Websites
GlaxoSmithKline PLC
Natlawreview· 23 Nov 2017

GlaxoSmithKline v. Glenmark Pharms

Wednesday, November 22, 2017 Addressing objections to a magistrate’s report and recommendation, a Delaware district court held that a generic manufacturer’s label showing an intent to induce infringement was not enough on its own to establish induced infringement in a post-launch case, and that evidence of actual inducement was required.

  • GlaxoSmithKline PLC
  • Regulatory & Legal
  • Company Websites
Boehringer Ingelheim GmbH
Zenopa· 23 Nov 2017

Boehringer Ingelheim launches new portal to facilitate access to research assets

Boehringer Ingelheim launches new portal to facilitate access to research assets 22 November 2017 Pharmaceutical Company Product News Boehringer Ingelheim has announced the launch of opnMe.com, a new platform offering free and open access to many of its medical assets for research purposes.

  • Boehringer Ingelheim GmbH
  • New Offerings
  • Press Releases
  • Company Websites
N
Bayer AG
Drug Discovery & Developement· 23 Nov 2017

Loxo Oncology & Bayer Form Development Partnership for Larotrectinib and LOXO-195

Loxo Oncology, a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that it has entered into a global collaboration with Bayer to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancers.

  • Loxo Oncology, Inc.
  • Bayer AG
  • Partnerships & Alliances
  • News Articles
  • News and Other Websites
N
GlaxoSmithKline PLC
Businesswire· 23 Nov 2017

GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

  • GlaxoSmithKline PLC
  • Regulatory & Legal
  • Press Releases
  • Wired News
Pfizer Inc.
News4J· 23 Nov 2017

Breaking down the stats in today’s market share for: Pfizer Inc. (PFE)

The market cap of 211.84B for Pfizer Inc. in today’s market indicated its current strength, making the company’s shares a lucrative one. The company’s existing price is $35.35 with a change in volume of 11,815,939.00. Pfizer Inc.’s target price was set to $38.47 with an IPO date at 6/1/1972.

  • Pfizer Inc.
  • Competitive Landscape
  • Company Websites
N
Monsanto Company
Reuters· 23 Nov 2017

Brazil's review of Bayer's Monsanto takeover may take be extended

SAO PAULO, Nov 22 (Reuters) - Brazil’s antitrust agency Cade could extend by as up to 90 days its analysis of the takeover of seeds company Monsanto Co. by Bayer AG, according to a regulatory filing posted on the watchdog’s website on Wednesday.

  • Monsanto Company
  • Bayer AG
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
  • Celgene Corp
  • Events
  • Social Updates
  • Twitter
AstraZeneca PLC
Patientdaily· 22 Nov 2017

AstraZeneca, MedImmune deliver 28 presentations at AHA Scientific Sessions

AstraZeneca and MedImmune, its department for global biologics research and development, recently gave 28 presentations at the American Heart Association (AHA) Scientific Sessions, which took place Nov. 11-15 in Anaheim, California. The presentations, which included reports on two late-breaking trials, focused on the company’s goals to help treat cardiovascular, renal and metabolic diseases (CVMD), according to an AstraZeneca press release.

  • AstraZeneca PLC
  • Medimmune LLC
  • Events
  • Company Websites
AstraZeneca PLC
Patientdaily· 22 Nov 2017

AstraZeneca's benralizumab receives positive opinion from European Medicines Agency's CHMP

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion of AstraZeneca's and MedImmune's benralizumab, which is designed to treat adults with severe eosinophilic asthma.

  • AstraZeneca PLC
  • Regulatory & Legal
  • Company Websites
Twitter· 22 Nov 2017

Upcoming Event | Catalent at the Drug Delivery to the Lungs Conference #DDL | December 6-8 in Edinburgh, Scotland | http://ow.ly/zH2q30gHB6Z

Drug Delivery to the Lungs Conference (DDL)
Date: December 6 - 8, 2017 Location: Edinburgh, Scotland Stand: 348 DDL provides an annual forum for scientists, academics, clinicians, regulatory and industry specialists invol...
  • Catalent Inc
  • Events
  • Social Updates
  • Twitter
AstraZeneca PLC
Pharmaphorum· 22 Nov 2017

Roundtable participant biography – Gunnar Brandrup-Wognsen, Global Medical Affairs Leader, AstraZeneca

Earlier this year, AstraZeneca sponsored a roundtable debate on the topic of secondary prevention of recurrent atherothrombotic events. Gunnar Brandrup-Wognsen took part as a member of the multi-perspective panel charged with building authority and thought leadership on this topic.

  • AstraZeneca PLC
  • Events
  • Company Websites
Bayer AG
Bbj· 22 Nov 2017

Bayer Hungária appoints head of government relations

Bayer Hungária appoints head of government relations BBJ Zsuzsanna Benyó will head the new position of government relations and communications manager at pharmaceuticals company Bayer Hungária. She will coordinate local planning and implementation of the proposed Bayer-Monsanto integration, according to a press release sent to the Budapest Business Journal.

  • Bayer AG
  • Management Changes
  • Company Websites
Pfizer Inc.
Thepharmaletter· 22 Nov 2017

BRIEF—Roche takes swipe at Pfizer over Herceptin biosimilar

Swiss drugmaker Roche is suing Pfizer, the world’s biggest pharma company, over alleged infringements of patents relating to the cancer drug Herceptin (trastuzumab). Roche’s Genentech unit has filed the case in a US court, claiming that Pfizer is infringing 40 patents with biosimilar version of the drug, reports Bloomberg.

  • Pfizer Inc.
  • Roberts Pharmaceuticals
  • Regulatory & Legal
  • Negative News
  • Company Websites
N
Allergan Inc
Fiercepharma· 22 Nov 2017

Allergan sued for scheming to protect Restasis—and it’s not just about the tribal license

Allergan has taken intense heat lately for trying to protect its big-selling Restasis from rivals by licensing patents to a Native American tribe. But according to a new lawsuit, the company's anticompetitive ploys date back several years.

  • Allergan Inc
  • Regulatory & Legal
  • Negative News
  • News Articles
  • News and Other Websites
Abbott Diabetes Care
Pharmiweb· 22 Nov 2017

Bristol-Myers Squibb to Take Part in Evercore ISI Biopharma Conference

Select a company 4d Pharma PLC Abbott Diabetes Care Abbott Laboratories Accelsiors Accord Healthcare ACI Group Ltd - Allchem Pharma Actelion Pharmaceuticals Ltd AD Instruments ADAllen Pharma ADAMAS Consulting ADDS (Advanced Drug Development Services) Adecco

  • Abbott Diabetes Care
  • Bristol-Myers Squibb Co
  • Select Group
  • Actelion Pharmaceuticals Ltd
  • Events
  • Company Websites
1 2 3 4 5